KAT2B

Across TCGA pan-cancer cohorts, KAT2B Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KAT2B data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher KAT2B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KAT2B expression acts as an unfavorable survival marker.

KIRP, PRAD, and BLCA are the cancer types where KAT2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	II,III,IV	0.148	0.771	<.001	24	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
BLCA	DFS	Median	All	0.231	0.522	.040	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	0.192	0.712	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KAT2B–KIRP (OS)

Open the KIRP breakdown →